Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

[{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicines","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze\u00ae in The US","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ohara Pharmaceutical"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SERB Receives Positive CHMP Opinion for Voraxaze\u00ae (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Serb"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Serb

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SERB Receives Positive CHMP Opinion for Voraxaze® (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Details:

Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further systemic damage.

Lead Product(s): Glucarpidase

Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 25, 2021

ASK
US

Upload
your Pipeline Activity

Ohara Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze® in The US

Details:

Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

Lead Product(s): Glucarpidase

Therapeutic Area: Pharmacology/Toxicology Product Name: Megludase

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 28, 2021

ASK
US

Upload
your Pipeline Activity

Hikma Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose

Details:

KLOXXADOTM contains twice as much naloxone per spray as Narcan® Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.

Lead Product(s): Naloxone Hydrochloride

Therapeutic Area: Pharmacology/Toxicology Product Name: Kloxxado

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2021

ASK
US

Upload
your Pipeline Activity

BTG Specialty Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicines

Details:

BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.

Lead Product(s): Glucarpidase

Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Serb

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 02, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY